SOLID TUMOR, ADULT

This trial tests a new genetic vaccine called Nous-209, combined with the drug pembrolizumab, in adults with specific types of cancer that have a genetic flaw called MSI-H or dMMR. The cancers studied include colorectal, stomach, and gastro-esophageal junction tumors that cannot …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific gene change (FGFR3). The goal is to find a safe dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard tre…

This early-phase trial tests a custom-made vaccine that uses a patient's own immune cells to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given together with two immunotherapy drugs (anti-PD-1 and anti-CTLA4) to boost the immune system's attack on adv…

This study tests a new drug called CTL-002 (visugromab) given alone or with an approved immunotherapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help control the cancer. About 263 adult…

This early-phase study tests whether a drug called AZD1390, given together with a precise type of radiation (SBRT), is safe for people whose solid tumors have spread to other parts of the body. About 54 adults with metastatic cancer will receive increasing doses of the drug along…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers, including lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and with other treatments. Researchers also want to…

This early-phase study tests a new drug called 3D185 in adults with advanced solid tumors who have no standard treatment left. The main goal is to check the drug's safety and how the body processes it. A small number of participants (42) will receive the drug to see if it can hel…

This study tests an experimental drug called ICT01, which tries to activate a special type of immune cell (gamma delta T cells) to fight cancer. It is for people with advanced solid tumors or blood cancers that have not responded to other treatments. The study first finds a safe …

This study tests a new proton therapy device, PROTEUS PLUS, in 47 adults with solid tumors. The goal is to see if it safely controls tumor growth. Participants receive targeted radiation, and researchers track side effects and disease response over time.

This study tests a new proton therapy machine called PROTEUS® PLUS in 47 adults with solid tumors. The goal is to see if it is safe and effective at controlling cancer. Researchers will measure how well the treatment shrinks or stops tumor growth and track any side effects.

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own tumor cells to create a vaccine that stimulates their immune system to fight the canc…

This early-stage study tests a new drug called IOS-1002, alone or with pembrolizumab, in about 140 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. Researchers will also look for signs that …

This study tests an experimental drug called KIN-2787, taken as a pill, in about 400 adults with advanced solid tumors (like lung cancer or melanoma) that have certain gene changes (BRAF or NRAS). The main goals are to check safety, find the best dose, and see if the drug can shr…

This early-phase study tests a new drug called IMA401 in about 95 adults with advanced solid tumors (like lung or head/neck cancer) that came back or didn't respond to prior treatments. IMA401 is a special immune molecule that helps the body's T cells attack cancer cells. The stu…

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This early-phase study tests an experimental drug called DECOY20, given alone or with another drug (tislelizumab), in about 120 adults with advanced solid tumors like liver, colorectal, pancreatic, lung, head and neck, bladder, or MSI-high cancers. The main goals are to check saf…

This study tests a new proton therapy machine (PROTEUS® PLUS) in 47 adults with solid tumors. The goal is to see if it safely controls tumor growth. Participants receive targeted radiation, and researchers track side effects and disease response over time.

This study tests whether benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The drug works by lowering eosinophil levels in the blood. About 51 adults with solid tumors or blood cancers who have moderate to severe skin reactions are…

This study enrolls 120 people with different cancers who already received treatment in an earlier study. The goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.

This study looks at whether regularly measuring the amount of paclitaxel (a chemotherapy drug) in the blood can help doctors give the right dose to kill cancer while limiting nerve damage. About 22 adults with various solid tumors (like lung, breast, or ovarian cancer) will have …